Oramed Pharmaceuticals (ORMP) Short Interest Ratio & Short Volume $2.15 -0.05 (-2.27%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.15 +0.00 (+0.23%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Oramed Pharmaceuticals Short Interest DataOramed Pharmaceuticals (ORMP) has a short interest of 650,800 shares, representing 1.87% of the float (the number of shares available for trading by the public). This marks a -2.08% decrease in short interest from the previous month. The short interest ratio (days to cover) is 2.7, indicating that it would take 2.7 days of the average trading volume of 155,764 shares to cover all short positions.Current Short Interest650,800 sharesPrevious Short Interest664,600 sharesChange Vs. Previous Month-2.08%Dollar Volume Sold Short$1.39 millionShort Interest Ratio2.7 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares40,850,000 sharesShort Percent of Float1.87%Today's Trading Volume35,166 sharesAverage Trading Volume155,764 sharesToday's Volume Vs. Average23% Short Selling Oramed Pharmaceuticals? Sign up to receive the latest short interest report for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartORMP Short Interest Over TimeORMP Days to Cover Over TimeORMP Percentage of Float Shorted Over Time Oramed Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/2025650,800 shares $1.39 million -2.1%1.9%2.7 $2.14 3/15/2025664,600 shares $1.59 million +7.9%1.9%2.6 $2.39 2/28/2025616,000 shares $1.29 million +6.9%1.8%2.2 $2.09 2/15/2025576,400 shares $1.38 million +149.0%1.7%2.1 $2.40 1/31/2025231,500 shares $518,560.00 -6.7%N/A0.9 $2.24 1/15/2025248,200 shares $580,788.00 +2.4%N/A1.6 $2.34 12/31/2024242,300 shares $586,366.00 -16.9%N/A1.7 $2.42 12/15/2024291,400 shares $719,758.00 -2.7%N/A2.2 $2.47 11/30/2024299,500 shares $709,815.00 -4.6%N/A2.4 $2.37 11/15/2024313,900 shares $699,997.00 +4.6%N/A3.1 $2.23 Get the Latest News and Ratings for ORMP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 10/31/2024300,000 shares $714,000.00 +0.5%N/A3 $2.38 10/15/2024298,500 shares $701,475.00 -12.3%N/A3 $2.35 9/30/2024340,400 shares $830,576.00 -4.0%N/A3.4 $2.44 9/15/2024354,400 shares $882,456.00 -2.4%N/A2.9 $2.49 8/31/2024363,200 shares $868,048.00 +53.0%N/A2.7 $2.39 8/15/2024237,400 shares $557,890.00 -14.6%N/A1.7 $2.35 7/31/2024278,100 shares $709,155.00 -16.9%N/A2.1 $2.55 7/15/2024334,700 shares $846,791.00 -36.7%N/A2.7 $2.53 6/30/2024529,100 shares $1.36 million +13.1%N/A4 $2.57 6/15/2024467,800 shares $1.05 million +63.3%N/A4 $2.25 5/31/2024286,500 shares $624,570.00 -5.9%N/A2.6 $2.18 5/15/2024304,600 shares $727,994.00 -6.2%N/A2.5 $2.39 4/30/2024324,600 shares $753,072.00 -11.7%N/A2.2 $2.32 4/15/2024367,600 shares $889,592.00 -37.0%N/A2.2 $2.42 3/31/2024583,900 shares $1.70 million +20.6%N/A3.3 $2.92 3/15/2024484,000 shares $1.41 million -3.3%N/A2.6 $2.92 2/29/2024500,700 shares $1.65 million -27.6%N/A2.5 $3.29 2/15/2024691,600 shares $2.17 million +76.0%N/A3.6 $3.14 1/31/2024393,000 shares $1.18 million +5.3%N/A2.1 $3.00 1/15/2024373,200 shares $873,288.00 +17.4%N/A1.8 $2.34 12/31/2023318,000 shares $734,580.00 -15.4%N/A1.6 $2.31 12/15/2023376,000 shares $827,200.00 -10.0%N/A2 $2.20 11/30/2023417,800 shares $927,516.00 -10.3%N/A2.4 $2.22 11/15/2023465,900 shares $959,754.00 +3.6%N/A2.6 $2.06 10/31/2023449,800 shares $823,134.00 -23.6%N/A2.5 $1.83 10/15/2023588,400 shares $1.28 million -2.2%N/A3.5 $2.18 9/30/2023601,800 shares $1.57 million +6.3%N/A3.4 $2.61 9/15/2023566,200 shares $1.72 million +25.8%N/A2.8 $3.04 8/31/2023450,000 shares $1.48 million -13.7%N/A1.8 $3.28 8/15/2023521,600 shares $1.63 million +4.0%N/A1.4 $3.13New “Trump” currency proposed in DC (Ad)Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. For the moment, you can watch this interview free of charge – just click here. 7/31/2023501,400 shares $1.70 million -25.9%N/A0.6 $3.39 7/15/2023677,000 shares $2.17 million -15.1%N/A0.8 $3.21 6/30/2023797,800 shares $2.86 million -6.5%N/A0.9 $3.58 6/15/2023852,900 shares $3.45 million -7.6%N/A0.9 $4.04 5/31/2023923,300 shares $3.73 million +89.9%N/A1 $4.04 5/15/2023486,300 shares $1.52 million -6.6%N/A0.5 $3.13 4/30/2023520,400 shares $1.18 million -33.4%N/A0.7 $2.27 4/15/2023781,200 shares $1.75 million -1.0%N/A0.9 $2.24 3/31/2023789,300 shares $1.72 million -19.9%N/A0.5 $2.18 3/15/2023985,700 shares $1.99 million -7.0%N/A0.6 $2.02 2/28/20231,060,000 shares $2.23 million +8.3%N/A0.6 $2.10 2/15/2023978,500 shares $2.15 million +3.4%N/A0.6 $2.20 1/31/2023946,000 shares $1.88 million -65.6%N/A0.6 $1.99 1/15/20232,750,000 shares $6.19 million -2.5%N/A2.1 $2.25 12/30/20222,820,000 shares $33.92 million +4.8%N/A6.9 $12.03 12/15/20222,690,000 shares $22.00 million -2.2%N/A9.1 $8.18 11/30/20222,750,000 shares $23.24 million -5.5%N/A10.5 $8.45 11/15/20222,910,000 shares $26.19 million -3.6%N/A10.9 $9.00 10/31/20223,020,000 shares $21.47 million +0.7%N/A11 $7.11 10/15/20223,000,000 shares $18.72 million -3.2%N/A9.4 $6.24 9/30/20223,100,000 shares $20.09 million +4.7%N/A3.7 $6.48 9/15/20222,960,000 shares $24.92 million -0.3%N/A2.3 $8.42 8/31/20222,970,000 shares $25.42 million -0.7%N/A2.2 $8.56 8/15/20222,990,000 shares $29.63 million -6.9%N/A2.1 $9.91 7/31/20223,210,000 shares $28.18 million -10.6%N/A2.1 $8.78 7/15/20223,590,000 shares $28.65 million +30.1%N/A2.3 $7.98 6/30/20222,760,000 shares $12.64 million -25.4%N/A1.8 $4.58 6/15/20223,700,000 shares $14.65 million +12.8%30.1%4.7 $3.96 5/31/20223,280,000 shares $15.19 million +1.6%N/A5.1 $4.63 5/15/20223,230,000 shares $14.76 million +26.2%N/A5.3 $4.57 4/30/20222,560,000 shares $13.16 million +15.8%N/A4.8 $5.14 4/15/20222,210,000 shares $15.16 million -6.8%N/A3.6 $6.86 3/31/20222,370,000 shares $20.50 million +4.9%N/A3.8 $8.65 3/15/20222,260,000 shares $20.05 million +2.7%N/A3.1 $8.87 2/28/20222,200,000 shares $22.66 million -2.2%N/A2.8 $10.30 2/15/20222,250,000 shares $26.15 million +2.3%N/A2.5 $11.62 1/31/20222,200,000 shares $19.71 million +9.5%N/A2.3 $8.96 1/15/20222,010,000 shares $22.21 million -9.1%N/A2.2 $11.05 12/31/20212,210,000 shares $31.56 million +10.0%N/A2.6 $14.28 12/15/20212,010,000 shares $30.33 million +122.9%N/A2.5 $15.09 11/30/2021901,600 shares $17.33 million -3.4%N/A1.1 $19.22 11/15/2021933,400 shares $26.28 million -3.5%N/A1.2 $28.16 10/29/2021967,400 shares $22.65 million -7.9%N/A1.2 $23.41 10/15/20211,050,000 shares $23.16 million -3.7%3.7%1.3 $22.06 9/30/20211,090,000 shares $23.96 million -2.7%3.8%1.2 $21.98 9/15/20211,120,000 shares $21.78 million -5.9%3.9%1.3 $19.45 8/31/20211,190,000 shares $23.42 million -13.8%4.2%1.5 $19.68 8/13/20211,380,000 shares $24.40 million -27.8%4.9%1.8 $17.68 7/30/20211,910,000 shares $27.10 million -14.7%6.9%2.8 $14.19 7/15/20212,240,000 shares $28.45 million -6.3%8.1%4.1 $12.70New “Trump” currency proposed in DC (Ad)Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. For the moment, you can watch this interview free of charge – just click here. 6/30/20212,390,000 shares $31.98 million +10.7%8.9%4.7 $13.38 6/15/20212,160,000 shares $28.84 million -12.9%8.0%4.7 $13.35 5/28/20212,480,000 shares $28.57 million -0.8%9.6%3.8 $11.52 5/14/20212,500,000 shares $25.65 million +7.3%9.7%4 $10.26 4/30/20212,330,000 shares $25.33 million +4.5%9.1%3.4 $10.87 4/15/20212,230,000 shares $20.69 million +0.5%8.7%2.6 $9.28 3/31/20212,220,000 shares $22.44 million +22.7%9.0%2.7 $10.11 3/15/20211,810,000 shares $17.01 million +4.0%7.4%2.2 $9.40 2/26/20211,740,000 shares $15.57 million -4.4%7.1%2.6 $8.95 2/12/20211,820,000 shares $18.56 million +45.6%7.6%2 $10.20 1/29/20211,250,000 shares $8.74 million +54.8%5.3%1.5 $7.00 1/15/2021807,700 shares $3.60 million No Change3.8%1.3 $4.46 ORMP Short Interest - Frequently Asked Questions What is Oramed Pharmaceuticals' current short interest? Short interest is the volume of Oramed Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 650,800 shares of ORMP short. 1.87% of Oramed Pharmaceuticals' shares are currently sold short. Learn More on Oramed Pharmaceuticals' current short interest. What is a good short interest ratio for Oramed Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ORMP shares currently have a short interest ratio of 3.0. Learn More on Oramed Pharmaceuticals's short interest ratio. Which institutional investors are shorting Oramed Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Oramed Pharmaceuticals: Group One Trading LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Oramed Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.87% of Oramed Pharmaceuticals' floating shares are currently sold short. Is Oramed Pharmaceuticals' short interest increasing or decreasing? Oramed Pharmaceuticals saw a decline in short interest in March. As of March 31st, there was short interest totaling 650,800 shares, a decline of 2.1% from the previous total of 664,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Oramed Pharmaceuticals' short interest compare to its competitors? 1.87% of Oramed Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Oramed Pharmaceuticals: Eton Pharmaceuticals, Inc. (1.55%), Verve Therapeutics, Inc. (25.15%), ORIC Pharmaceuticals, Inc. (22.51%), Tourmaline Bio, Inc. (20.14%), Kamada Ltd. (0.11%), Rapport Therapeutics (16.08%), Altimmune, Inc. (31.99%), Autolus Therapeutics plc (5.01%), Erasca, Inc. (16.62%), SNDL Inc. (1.39%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short Oramed Pharmaceuticals stock? Short selling ORMP is an investing strategy that aims to generate trading profit from Oramed Pharmaceuticals as its price is falling. ORMP shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Oramed Pharmaceuticals? A short squeeze for Oramed Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ORMP, which in turn drives the price of the stock up even further. How often is Oramed Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ORMP, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies Eton Pharmaceuticals Short Interest Data Verve Therapeutics Short Interest Data ORIC Pharmaceuticals Short Interest Data Tourmaline Bio Short Interest Data Kamada Short Interest Data Rapport Therapeutics Short Interest Data Altimmune Short Interest Data Autolus Therapeutics Short Interest Data Erasca Short Interest Data SNDL Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ORMP) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
